19 China COVID-19 Antigen Detection Reagents Have Been Approved and Included in Medical Insurance in Many Places, With a Minimum Of 5 CNY per person

On March 23, after review by the State Food and Drug Administration, two COVID-19 antigen detection reagent products were approved. As of March 23, the State Food and Drug Administration has approved 19 new coronavirus antigen detection reagent products. The COVID-19 antigen detection reagent is suitable for the population specified in the "COVID-19 Antigen Detection Application Plan (Trial)".

At present, the State Food and Drug Administration has approved 19 COVID-19 antigen detection reagents, which have been included in medical insurance reimbursement in many places, with a minimum of 5 yuan (CNY) per person.

On March 24, the Office of the Hunan Healthcare Security Administration issued the "Notice on Effectively Doing a Good Job in the Current Epidemic Prevention and Control Medical Security Work", which clearly temporarily included the COVID-19 antigen detection reagents and corresponding testing items into the basic medical insurance medical service items of Hunan Province. Relevant expenses incurred by insured persons in designated primary medical institutions shall be paid in accordance with the policies of Class A medical service items; the expenses of purchasing testing reagents in designated retail pharmacies can be paid using personal accounts.

On March 24, the Jiangsu Healthcare Security issued a notice for the current epidemic prevention and control, requiring medical security departments at all levels in the province to comprehensively consider the needs of epidemic prevention and control, and adjust and optimize medical insurance policies in a timely manner. The COVID-19 antigen detection reagents and corresponding detection items will be temporarily included in the catalogue of medical service items of basic medical insurance.

On March 23, the Shanxi Healthcare Security reported that Shanxi Province has clearly included the COVID-19 antigen test and drugs into the province's medical insurance reimbursement scope. Insured patients who undergo testing during hospitalization shall be reimbursed according to Class B consumables and items; outpatient testing in medical institutions and reagents purchased in retail pharmacies can be paid from personal account funds.

On March 23, the Gansu Healthcare Security issued a notice on regular province-wide health protection work. The "Notice" applies the relevant medical insurance coverage for the COVID-19 infection detection, the treatment of the coronavirus, and the emergency payment of medical expenses. Antigen detection service fee is 5 yuan (CNY) per person, and it is temporarily included in the medical insurance.

From March 25, the novel coronavirus antigen test was temporarily included in the scope of medical insurance payment in Fujian Province. The Fujian Healthcare Security issued the "Notice on Issues Concerning the Prices of New Coronavirus Antigen Testing Items" to clarify matters related to the prices of COVID-19 antigen testing items. Relevant public medical institutions carry out the "new coronavirus antigen testing project" according to regulations at 5 yuan (CNY) per person.

The test kits (including sampling equipment) are temporarily charged no more than 15 yuan per person. For those who simply carry out the new coronavirus antigen test, the public does not need to register, and public medical institutions are not allowed to charge general outpatient examination fees or general diagnosis and treatment fees. For patients taking self-tests, public medical institutions shall not charge fees for antigen testing items.